JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Scholar Rock (NASDAQ:SRRK) Stock

Scholar Rock (NASDAQ:SRRK) had its price target raised by stock analysts at JPMorgan Chase & Co. from $47.00 to $50.00 in a report issued on Monday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s target price indicates a potential upside of 23.51% from the stock’s previous close.

A number of other research analysts also recently weighed in on SRRK. Piper Sandler raised their price objective on Scholar Rock from $51.00 to $58.00 and gave the company an “overweight” rating in a research note on Wednesday, March 4th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Scholar Rock in a research report on Thursday, January 22nd. Barclays increased their price target on Scholar Rock from $52.00 to $53.00 and gave the company an “overweight” rating in a report on Tuesday, March 3rd. UBS Group began coverage on shares of Scholar Rock in a research note on Wednesday, January 7th. They issued a “buy” rating and a $60.00 price objective for the company. Finally, Truist Financial upped their price objective on shares of Scholar Rock from $44.00 to $55.00 and gave the stock a “buy” rating in a report on Tuesday, March 3rd. Four equities research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $54.36.

Scholar Rock Stock Up 1.2%

SRRK stock traded up $0.47 during midday trading on Monday, reaching $40.48. The company had a trading volume of 516,711 shares, compared to its average volume of 1,104,140. Scholar Rock has a 1 year low of $22.71 and a 1 year high of $49.82. The company has a current ratio of 6.95, a quick ratio of 6.95 and a debt-to-equity ratio of 0.41. The company has a market capitalization of $4.65 billion, a P/E ratio of -11.82 and a beta of 0.70. The company has a 50 day moving average of $45.21 and a two-hundred day moving average of $39.68.

Scholar Rock (NASDAQ:SRRK) last issued its earnings results on Tuesday, March 3rd. The company reported ($0.76) EPS for the quarter, beating analysts’ consensus estimates of ($0.86) by $0.10. During the same period in the previous year, the company posted ($0.64) earnings per share. On average, equities research analysts expect that Scholar Rock will post -2.42 earnings per share for the current fiscal year.

Insider Activity at Scholar Rock

In other news, insider Jing L. Marantz sold 4,157 shares of the stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $46.53, for a total value of $193,425.21. Following the completion of the transaction, the insider owned 126,012 shares in the company, valued at approximately $5,863,338.36. This represents a 3.19% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Caryn Parlavecchio sold 9,035 shares of the firm’s stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $46.53, for a total transaction of $420,398.55. Following the transaction, the insider owned 169,087 shares of the company’s stock, valued at approximately $7,867,618.11. This represents a 5.07% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 208,470 shares of company stock worth $9,201,778 in the last three months. Corporate insiders own 13.30% of the company’s stock.

Institutional Trading of Scholar Rock

Several institutional investors have recently bought and sold shares of the stock. IFP Advisors Inc grew its position in Scholar Rock by 294.1% in the fourth quarter. IFP Advisors Inc now owns 603 shares of the company’s stock valued at $27,000 after acquiring an additional 450 shares during the period. Caitong International Asset Management Co. Ltd bought a new position in shares of Scholar Rock during the fourth quarter valued at $30,000. Summit Securities Group LLC acquired a new stake in shares of Scholar Rock in the 4th quarter valued at $31,000. EverSource Wealth Advisors LLC boosted its stake in shares of Scholar Rock by 151.3% in the 4th quarter. EverSource Wealth Advisors LLC now owns 872 shares of the company’s stock valued at $38,000 after purchasing an additional 525 shares in the last quarter. Finally, Hilton Head Capital Partners LLC bought a new stake in shares of Scholar Rock in the 4th quarter worth about $44,000. Institutional investors and hedge funds own 91.08% of the company’s stock.

Scholar Rock Company Profile

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).